Neuvotion, Inc. is pioneering the development of brain-body interface (BBI) technology aimed at addressing movement impairments. Their innovative approach integrates artificial intelligence (AI) with highly-focal stimulation and brain-computer interface (BCI) compatible technologies. This combination is designed to provide significant therapeutic benefits, enabling clinicians to effectively facilitate and monitor patient progress both in-person and remotely. The company's focus on creating devices that enhance rehabilitation outcomes reflects their commitment to delivering advanced care solutions for individuals with paralysis and movement disorders.

The team at Neuvotion comprises experienced professionals from diverse backgrounds, including biomedical engineering, neurotechnology, and clinical medicine. Their collective expertise is directed towards creating revolutionary solutions in the rehabilitation space, particularly for spinal cord injuries and related conditions. By actively seeking feedback from researchers, clinicians, and patients, Neuvotion aims to refine its technologies and ensure they meet the needs of users effectively. This collaborative approach underscores their dedication to advancing therapeutic options in the growing outpatient rehabilitation market, which is projected to expand significantly in the coming years.

United States

Neuvotion is developing breakthrough solutions for facilitating and restoring movement. Our approach combines targeted neurostimulation and AI (artificial intelligence) to deliver unparalleled therapeutic value for patients with a movement disorder or impairment from stroke or injury. Neuvotion products allow doctors and therapists to leverage state-of-the-art technology, while monitoring patient progress in-person or remotely.

Neuvotion, Inc.

Company Details